FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
FiercePharma6h
Sanofi lays out €40M to beef up transplant, diabetes drug production in France
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...
Pharmabiz18h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
The Pharma Letter23h
FDA accepts Dupixent sBLA resubmission for CSU
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...